Immunomedics announced that results from the confirmatory Phase 3 ASCENT study showed that Trodelvy "significantly extended" overall survival and improved overall response rate and clinical benefit rate, compared to treatment of choice standard single-agent chemotherapy in brain metastases-negative patients with mTNBC who had previously received at least two prior therapies for metastatic disease. Despite having received a median of four prior anticancer regimens, patients treated with Trodelvy in the ASCENT study showed a statistically significant and clinically meaningful improvement in OS with a median of 12.1 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.48, the company said. Trodelvy also demonstrated a statistically significant improvement in ORR and CBR compared to chemotherapy, Immunomedics added. Ten complete responses were observed in the Trodelvy arm compared with two in the control group. As of data cutoff on March 11, 2020, 15 patients continued to receive Trodelvy treatment while no patient remained on study in the TPC control arm. "We believe these remarkable results should facilitate the establishment of Trodelvy as a new standard of care in patients with third-line mTNBC," said Dr. Loretta M. Itri, Chief Medical Officer of Immunomedics. "We are working very collaboratively with FDA under the RTOR program to submit a supplemental Biologics License Application to have Trodelvy's label expanded to include these confirmatory new data. Additionally, we plan to submit a Marketing Authorization Application to the European Medicines Agency in the first half of 2021 in order to make this important new treatment available to mTNBC patients in Europe."

Condor Hospitality Trust announced that it has terminated its merger agreement with NHT Operating Partnership, the operating partnership of NexPoint Hospitality Trust and certain of its affiliates, effective immediately. Pursuant to its rights under the merger agreement, the company terminated the merger agreement due to failure of NHT's operating partnership to consummate the acquisition of the company and for material breaches of the merger agreement by NHT's operating partnership and its affiliates. Pursuant to the merger agreement, the company is entitled to receive a termination fee of $11.93M within five business days of its termination of the merger agreement. The company continues to reserve all other rights and remedies.

In a regulatory filing, SiTime CEO Rajesh Vashist disclosed the sale of 30,000 common shares of the company on September 16th in a total transaction size of $2.0M.

Point72 Asset Management disclosed a 5.0% stake in Fulcrum Therapeutics, which represents over 1.38M shares. The filing does not allow for activism.

Point72 Asset Management disclosed a 7.3% stake in Dave & Buster's, which represents over 3.45M shares. The filing does not allow for activism.

Starwood Capital disclosed a 8.39% stake in MFA Financial, which represents over 38.0M shares. The filing does allow for activism. The filing indicates that the "Reporting Persons may communicate with the board of directors of the Issuer, members of management and/or other stockholders or other relevant parties from time to time with respect to operational, strategic, financial or governance matters or otherwise work with management and the board of directors with a view to maximizing stockholder value."

In a regulatory filing, Tutor Perini chairman and CEO Ronald N. Tutor disclosed the sale of 40,000 common shares of the company on September 17 at a price of $12.71 per share.

Granite Construction announced that it has received an extension for continued listing and trading of the company's common stock on the New York Stock Exchange, or NYSE. The extension of an additional six months gives the company until March 18, 2021 to file its annual report on Form 10-K for the year ended December 31, 2019 and its subsequent quarterly reports on Form 10-Q with the Securities and Exchange Commission, or SEC, subject to reassessment on an ongoing basis. The company can regain compliance at any time before that date by filing its 2019 Form 10-K and 2020 Form 10-Qs with the SEC. The NYSE will continue to closely monitor the company's restatement process and timing, and could initiate accelerated trading suspension prior to the end of the six-month extension if that process fails to progress satisfactorily during the extension. In addition, in the event the company does not file its 2019 Form 10-K and 2020 Form 10-Qs with the SEC by March 18, 2021, the NYSE will move forward with the initiation of suspension and delisting procedures.

Algonquin Power & Utilities Corp. announced the appointment of Arthur Kacprzak as Chief Financial Officer, assuming the role upon the retirement of CFO David Bronicheski. This transition is part of a multi-year initiative that was undertaken by APUC's Board of Directors to support a smooth shift to new leadership while maintaining the company's strong track record of growth and delivering long-term shareholder value. "I am extremely pleased to welcome Arthur into the CFO role," said Arun Banskota, President & Chief Executive Officer of Algonquin. "At $11 billion in assets, Algonquin is one of North America's fastest growing utilities, a global leader in renewable energy solutions, and a member of the blue chip TSX60 index. David's strong leadership and finance expertise over the last twelve years has contributed hugely to that success. We are immensely grateful for David's many contributions to Algonquin, and wish him much happiness in his retirement. I have full confidence that Arthur will continue the tradition of strong financial leadership and balance sheet management that has contributed over the years to Algonquin's long-term success."

NorthWestern Corporation d/b/a NorthWestern Energy announced that it is transferring its stock exchange listing from The New York Stock Exchange after the end of trading on September 30, 2020 to The Nasdaq Global Select Market. NorthWestern's shares will begin trading as a Nasdaq-listed security on October 1, 2020 and will continue to trade under the ticker symbol NWE.

In a regulatory filing, Broadcom chief legal officer Mark David Brazeal disclosed the sale of 2,000 common shares of the company on September 16 at a price of $367.54 per share.